IGC Pharma CEO Sells 200,000 Shares—What It Means for Investors
Insider selling by IGC Pharma CEO Mukunda Ram raises caution: a modest $54k sale amid rising insider trades and a low‑price stock, but a key watch is the Phase 2 CALMA trial results this fall.
3 minutes to read